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HEALTH UNDER A NATIONAL HEALTH INSURANCE PROGRAM IN 
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OBJECTIVES: Drug-eluting stents (DESs) have been considered to be generally supe-
rior to bare-metal stents (BMSs) for its lower rates of target-vessel revascularization. 
The National Health Insurance (NHI) started reimbursing BMSs in July 1999. But 
when it came to DESs, balanced-billing was employed to reimburse DESs under the 
pressure of NHI’s widening ﬁ nancial deﬁ cits. Patients who chose DESs would need to 
pay the differences between the price of DESs charged by providers and the fee sched-
ule of BMSs set by NHI. Whether distribution of DESs would concentrate in patients 
with higher socioeconomic status remained an unanswered research question. This 
study aimed to examine the inﬂ uence of socioeconomic factors on the choice between 
DESs and BMSs in Taiwan. METHODS: Patients who admitted in the hospitals for 
coronary stenting during December 1, 2006 to December 31, 2007 in the Taiwan 
National Health Insurance (NHI) claims database were identiﬁ ed as the study cases. 
The Cox proportional hazard model was preformed to evaluate the relationship 
between socioeconomic factors and the likelihood of choosing DESs, controlling for 
other patients’ demographical factors and providers’ characteristics. RESULTS: There 
were 3773 cases of DESs and 7413 BMSs in the observation period. Patients who 
were with higher wage income level and residing in the northern part of Taiwan were 
signiﬁ cantly more likely to choose DESs. Veterans and patients from low-income 
households were signiﬁ cantly less likely to choose DESs. CONCLUSIONS: Socioeco-
nomic factors seemed to be strong predictors of choosing DESs. Future research on 
the implications of disparities in using DESs is warranted to evaluate the impact of 
the balance-bill on equity of health in Taiwan. 
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OBJECTIVES: This study aims to evaluate potential drug-drug interactions (DDIs) 
related to angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor 
blockers (ARBs) in Taiwan. METHODS: This cross-sectional study used a claim-based 
dataset published by the Taiwanese National Health Research Institute, constituting 
of data for 1,000,000 beneﬁ ciaries randomly sampled in 2005 from the nationwide 
population and followed longitudinally from 1995 to 2008. Individual prescription 
data of hypertensive outpatients using ACEIs or ARBs were extracted from 2006 to 
2008. Level-1 to Level-3 potential DDIs were identiﬁ ed as the presence of interacting 
pairs deﬁ ned by the “Drug Facts and Comparisons.” Demographic of patients having 
potential DDIs, prescription details and prescription overlapping days (POD) were 
collected and presented in descriptive statistics. Frequency of potential DDIs was 
stratiﬁ ed by three age bands and four POD ranges and evaluated by Wald chi-square 
tests. RESULTS: Of all, 23,299 DDI prescriptions were assessed, including 22,967 
(98.58%) and 332 (1.42%) for ACEIs and ARBs. For ACEIs, the most common drug 
for potential Level-1 to Level-3 DDIs is amiloride (n = 3902, 16.99%), indomethacin 
(n = 624, 2.72%) and furosemide (n = 13137, 57.20%), respectively. For ARBs, the 
most frequent combined drug with Level-2 and Level-3 DDIs is lithium (n = 98, 
29.52%) and indomethacin (n = 234, 70.48%). The majority of patients who had 
used DDI prescriptions aged over than 45 years (in the age bands of “45–65 years” 
and “over 65 year”), and the most frequent POD range for DDI prescriptions is during 
16 to 30 days. CONCLUSIONS: Although there is only a small proportion of poten-
tial ACEIs/ARBs related DDI prescriptions in Taiwan, prescriptions are mostly pre-
scribed for mid-age and elderly patients and frequently continued for 1 month. Further 
study will still need to explore the association between potential DDI prescriptions 
and adverse outcomes to justify the appropriateness of these prescriptions. 
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OBJECTIVES: Upon the coverage restriction proposed by Taiwan National Health 
Insurance (NHI), the dual antiplatelet therapy (DAT) with clopidogrel and aspirin 
could be reimbursed up to 9 months for some speciﬁ c indications since 2004. The 
longer duration of DAT was allowed for the cases with drug eluting stent (DES) since 
late 2006. Although evidence showed its risks outweighed the beneﬁ ts comparing to 
use aspirin alone, it is a lack of study examining the population use of DAT in Taiwan. 
A secondary data analysis was performed to examine the use patterns of DAT, speciﬁ -
cally among the older adults in Taiwan. METHODS: A population-based longitudinal 
assessment was conducted using the 2003–2007 NHI databases. Those beneﬁ ciaries 
in 60 years old of age and greater during the study period were evaluated. All relevant 
data, including visits toward physician clinics, outpatient departments, use of medica-
tions, and pertinent covered cost in the datasets of ambulatory care were retrieved 
and analyzed. Descriptive analysis was performed to describe the utilization and 
duration of DAT. RESULTS: Of 1 million beneﬁ ciaries being evaluated, 1511 older 
patients (age = 70.8 ± 8.0-year-olds) were prescribed DAT. A sharply increasing 
prescription of DAT occurred in 2007. 85.6% were prescribed with approval indica-
tions (i.e., ischemic heart diseases) for aspirin or clopidogrel alone. Thirty-one percent 
possessed with at least one atherothrombotic risk factors (DM, dyslipidemia), which 
might attribute to DAT. The duration of DAT was up to 13 months. About 10% had 
DAT for more than 9 months. CONCLUSIONS: A sharply increasing utilization of 
DAT among Taiwanese older adults occurred in 2007. The change of reimbursement 
policy for DES in Taiwan may be the major contributing factor. However, further 
studies are needed to explore other contributing factors of DAT and its effectiveness 
and safety outcomes. 
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OF STATINS IN AUSTRALIA
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OBJECTIVES: To study the extent of brand substitution and brand switching between 
statins available on the Australian Pharmaceutical Beneﬁ t Scheme (PBS). METHODS: 
PBS prescription claims provided by Medicare Australia of a 10% random sample of 
all Australian long-term concession card holders were assessed over the time period 
August 2007 through July 2008. Patients had to ﬁ ll at least four prescriptions for a 
statin with generics (simvastatin [ﬁ ve strengths with up to 17 brands], or pravastatin 
[four strengths with up to 12 brands]) over the 1-year period. The proportion of 
non-switchers (single brand only) and multiple switchers (two or more switches 
between brands) were determined for each strength of these statins. RESULTS: A total 
of 39,913 patients ﬁ lled at least four prescriptions for a statin in the time window. 
The majority of Concessional patients received a single brand over the period (simv-
astatin at 60% and pravastatin at 56%). A smaller proportion received three or more 
brands: 14% for simvastatin to 13% for pravastatin. The proportion of statin scripts 
for the originator brand ranged from 22% for Zocor (simvastatin) to 36% for Prava-
chol (pravastatin). A substantial proportion of statin patients were multiple switchers: 
23% for simvastatin and 25% for pravastatin. Neither the number of brands received 
nor the number of switches seemed to be affected by the number of brands available 
on the PBS. Multiple switching was more common in of those under 50 years (33%) 
compared with of those aged 70–79 years (23%). CONCLUSIONS: There is potential 
for patient confusion since there are multiple switches of both statins occurring in one 
quarter of these Australian statin patients. There was also a 43% increase in multiple 
switching by younger patients. 
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OBJECTIVES: Angiotensin receptor blockers (ARBs) have been widely prescribed for 
multiple indications, ranging from heart failure to the prevention of kidney disease in 
patients with diabetes mellitus. The purpose of this study was to describe the utiliza-
tion, price and expenditure trends of ARBs. METHODS: A retrospective, descriptive 
time-series analysis was performed using the National Medicaid pharmacy claims 
database from 1991 to 2008. The quarterly prescription numbers and reimbursement 
amounts were calculated over time by summing data for individual drug products. 
The quarterly per-prescription reimbursement as a proxy for drug price was computed 
for the price of ARBs. RESULTS: ARB prescriptions increased from 0.03 million in 
1995 to 7.8 million in 2005, representing a 259-fold increase. For individual drugs, 
the two top selling drugs were Diovan® and Cozaar®, with 867,840 prescriptions 
and 340,101 prescriptions, respectively. In 2006, ARB prescriptions dropped due to 
the implementation of Medicare Part D. Just 2 years later, only 2.1 million were 
prescribed. Expenditure for ARBs increased from $1.3 million in 1995 to $515 million 
in 2005, and dropped to $174 million in 2008. Medicaid expenditure for ARBs 
reached the summit in 2005 quarter 4, which was almost $60 million. But after 
Medicare Part D was implemented, payment dropped until 2007 quarter 3 and started 
to increase to 23 million by the end of study period at 2008 quarter 4. The average 
payment per ARB prescription also increased from 36.22 in 1995 to 81.84 in 2008. 
CONCLUSIONS: Dramatically increased utilization of ARBs was observed from this 
study due to their wide therapeutic indications and efﬁ cacy. A signiﬁ cant drop in 
utilization occurred from 2006–2008 and was related to the introduction of Medicare 
Part D. Regardless of the entry of new drugs in the same pharmacologic category, the 
payment per prescription continued to rise during the study period. 
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DOWNSTREAM RESOURCE UTILIZATION? A DIFFERENCE-IN-
DIFFERENCES ANALYSIS
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OBJECTIVES: Diabetes affects 7.8% of the US population and is one of the most 
expensive medical conditions. The economic impact of statins, one of most effective 
cholesterol-lowering agents used today, is unclear. We sought to assess the impact of 
statin use on resource utilization among diabetes patients in the United States using 
a difference-in-differences analysis. METHODS: We identiﬁ ed and linked 858 
